Bioniz Therapeutics Provides Results from Multi-Cytokine Inhibitor BNZ-1 Clinical Study.
M2 PHARMA-July 20, 2017-Bioniz Therapeutics Provides Results from Multi-Cytokine Inhibitor BNZ-1 Clinical Study
(C)2017 M2 COMMUNICATIONS
- Irvine, California-based peptide therapeutics developer Bioniz Therapeutics, Inc. has released top-line results from its first-in-human study of BNZ-1, a novel IL-2/IL-9/L-15 inhibitor, the company said.
In the open-label, dose-escalation study (NCT03046459), 18 healthy volunteers were administered a single intravenous dose of BNZ-1 ranging from 0.2 mg/kg to 6.4 mg/kg followed by 30 days of safety monitoring and collection of pharmacokinetic and biomarker samples.
BNZ-1 was well-tolerated and generally considered safe, without any clinically significant laboratory abnormalities or dose limiting toxicities observed at any dose level.
Bioniz will initiate a multiple ascending dose study of BNZ-1 in healthy volunteers in Q3 2017 and plans to conduct future clinical trials of BNZ-1 in multiple patient populations, including the T-cell malignancies of Large Granular Lymphocyte Leukemia and Cutaneous T-cell Lymphoma, as well as for autoimmune indications, including Alopecia Areata.
The company's lead development candidate, BNZ-1, is a PEGylated peptide that functions as a selective and simultaneous inhibitor of cytokines IL-2, IL-9, and IL-15.
Bioniz is a clinical-stage biopharmaceutical company developing multi-cytokine inhibitory peptide therapeutics to address immuno-inflammatory diseases and cancer.
The company leverages its world class expertise in cytokine biology, originating in research conducted at the National Institutes of Health, to develop a novel approach to selectively inhibit functionally redundant cytokines while leaving the rest of the cytokine network intact.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Jul 20, 2017|
|Previous Article:||Imago BioSciences Begins Phase 2a of Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome.|
|Next Article:||CSL Behring's Supplemental Biologics License Application for Hizentra for CIPD Accepted for Review by FDA.|